GlassScriptPhysician profile
Muhammed A Rahman
NPI 1417934498
$1,806.27
in general payments reported to CMS, 2019-2025
14 companies · $72.28 in 2025
The $72.28 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $130 · 2021: $657 · 2022: $644 · 2023: $226 · 2024: $76.51 · 2025: $72.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $332.91 | 2020-2023 | Ingrezza |
| Alkermes, INC. | $304.50 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.05 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $204.89 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $190.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $189.90 | 2020-2025 | Rexulti |
| Abbvie INC. | $133.54 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $96.73 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.77 | 2024-2025 | Uzedy |
| Almatica Pharma LLC | $22.48 | 2022 | |
| Lundbeck LLC | $16.05 | 2022 | |
| Axsome Therapeutics, INC. | $13.86 | 2022 | |
| Eisai INC. | $13.79 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammed Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.